You are here
Lung cancer characteristics in 762 never- and 6,246 ever-smoker patients: Study KBP-2010-CPHG.
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).
Background: In 2010, the French College of General Hospital Respiratory Physicians performed a prospective multicenter epidemiological study to describe the baseline characteristics and management of all new cases of primary lung cancer and evaluate survival. The present abstract compares characteristics according to smoking. Methods: 7,051 patients ≥18 years presenting with primary lung cancer, histologically or cytologically diagnosed between 1 January and 31 December 2010, and followed-up in the respiratory department of one of the 104 general hospitals participating in the study, were included. A standardized form was completed for each patient at diagnosis. A steering committee checked inclusion exhaustiveness. Results: 762 patients were never-smoker and 6,246 ever-smoker (43 missing data). Respectively, 222, 635, and 5,088 of ever-smokers claimed to consume or to have consumed 1-10, 11-20, and >20 pack-year; their median smoking duration was 40 years. Former-smokers stopped smoking 12 years ago (median). 158 never-smokers claimed to have been exposed to passive-smoking. At diagnosis, statistical significant differences between never- and ever-smoker patients (p<0.0001) were found for sex (women: 70%/19%); age (median: 73/64 years); stage of cancer (IV: 71%/59%); cancer type (adenocarcinoma: 69%/43%; small-cell lung cancer: 5%/14%; squamous-cell carcinoma: 8%/28%); EGFR mutation exploration (51%/28%) and positivity (37%/5%). For all these characteristics, significant trends (p<0.0001) were also observed when patients were graded according to consumption: e.g., percentage of adenocarcinoma was 63%, 54%, 50%, and 41% in the 0, 1-10, 11-20, and >20 pack-year groups, respectively. Conclusions: This study confirms the main differences between never-smokers and ever-smokers, in particular on histological type and EGFR-mutation, two characteristics that impact treatment.
Abstracts by Daniel Coëtmeur:
Study KBP-2010-CPHG: Characteristics and management of 968 new cases of small-cell lung cancer (SCLC).Meeting: 2013 ASCO Annual Meeting | Abstract No: e19078